Drug intelligence / Profile preview

Zowell

Development stage: Preclinical
Lead developer: Biom Pharmaceutical
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Zowell is a microbiome-based product developed by Biom Pharmaceutical Corp (Biomr) under its CareBiom brand. It is designed as an adjunct therapy for cancer care, specifically aimed at modulating and protecting the human microbiome in patients undergoing treatments such as chemotherapy and radiation. The product is part of a precision oncology wellness program that seeks to mitigate treatment-induced dysbiosis and support the restoration of the core microbiome to improve patient outcomes and treatment tolerance. While specific clinical trial phases are not publicly detailed in a traditional drug pipeline, Zowell is positioned as a precision microbiome product intended to support the core human microbiome during intensive oncological interventions.

Brand names: Zowell

Beyond the preview

Go deeper on Zowell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zowell.

Explore the full profile